Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production. Nanoparticles Contract Manufacturing.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Pharmaceutical Technology

JULY 29, 2022

In preparation for this, drug manufacturing will begin later this year and will be outsourced to external contract manufacturing organisations (CMOs). The most common marketed drugs in this space aim to address the hyperammonaemia caused by the defective genes in this disorder.

RNA 245

RNA Gene Expression Gene Gene Therapy 245

The Pharma Data

MARCH 1, 2022

A key element of this partnership involves Lifebit’s CloudOS platform – a powerful, secure and cutting-edge platform used by a growing number of research organizations and governments globally, such as Genomics England and The Hong Kong Genome Project. Source link: [link].

Biobanking 52

Biobanking Genome Genomics Genome Project 52

The Pharma Data

JUNE 2, 2022

A*STAR’s Genome Institute of Singapore (GIS) and Institute of Bioengineering & Bioimaging (IBB) generated antibodies which exclusively target antigens that were initially identified from gastric cancer cells. The technology used to identify the unique A*STAR antibodies resulted from a multi-institutional collaboration in Singapore.

Antibody 52

Antibody Licensing Licensing Development 52

The Pharma Data

SEPTEMBER 11, 2021

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.

Antibody 52

Antibody DNA Containment Manufacturing 52

Drug Discovery World

SEPTEMBER 6, 2022

Indeed, the growth of the cell and gene therapy market, coupled with the demand that the pandemic placed on manufacturing capacity, means the industry faces shortages of these crucial materials. The challenge for the market then, according to Boissel, is how much can a payor afford to pay upfront? .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

The Pharma Data

NOVEMBER 15, 2020

Prior to Celgene, she held leadership roles in marketing, sales and new business development from 2002 to 2011 at Johnson & Johnson. She earned a BA from Durham University, U.K., and an MBA from Harvard Business School. Most recently, she was a senior executive at Celgene Corporation, where she led corporate strategy from 2012 to 2017.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40